Judge Saylor denied GSK’s first Motion to Dismiss all of the pending Zofran cases on preemption grounds last year. Read more
Zofran is a powerful anti-nausea medication approved by the FDA for patients suffering from nausea as a side effect of chemotherapy. Read more
Zofran continues to be prescribed routinely for pregnant women suffering from morning sickness. Read more
The whistleblower suit was filed in New Jersey, contending the employee was fired for speaking out about unreliable study results that have underpinned the deceptive marketing of a smoking c... Read more
While the negotiated deal benefited Teva and GSK, the deal was not structured with any concern or interest for purchasers or consumers who need treatment for epilepsy, bipolar disorder, and... Read more
Despite knowing these risks, GSK claimed that Paxil was safer and more effective than other selective serotonin reuptake inhibitors, (SSRIs), on the market, and made marketing misrepresentat... Read more
GlaxoSmithKline PLC has been fined a record 3 billion yuan ($488.5 million) for bribing doctors. A verdict was handed down by a Chinese court, which also sentenced several of the drugmaker’s... Read more
GlaxoSmithKline PLC (GSK) has agreed in another settlement to pay $105 million to 44 states and the District of Columbia. This settlement resolves allegations that the company improperly mar... Read more
A New Jersey federal jury has returned a $106.7 million verdict against GlaxoSmithKline LLC (GSK) in a suit brought by Mylan Inc. The jury found that GSK breached an exclusive contract by al... Read more
In a groundbreaking ruling, an Illinois federal judge determined that GlaxoSmithKline PLC (GSK) can be held liable for a corporate and securities lawyer’s suicide. The lawyer had taken a gen... Read more
If you would like to subscribe to the Jere Beasley Report digital edition, simply visit our Subscriptions page and provide the necessary information or call us at 800-898-2034.
Attorney Advertising - Prior results do not guarantee a similar outcome.